
Giampaolo Bianchini: Out on Nature our work ‘Spatial predictors of immunotherapy response in triple-negative breast cancer’ lead by Ali Lab and myself.
Quoting Giampaolo Bianchini, the Head of the Translational and Immunotherapy research group at the San Raffaele Scientific Institute, Milan, on X/Twitter:
”Out on Nature our work ‘Spatial predictors of immunotherapy response in triple-negative breast cancer’ lead by Ali Lab and myself. To work, immunotherapy requires certain immune cell types, in proper functional state and spatial context.
Immune checkpoint blockade (ICB) improves TNBC outcome in both metastatic and early setting, but biological determinants of individual benefit, especially in early setting, are unknown Precision immunology in breast cancer is a major unmet need.
43 proteins were quantified at single-cell resolution by Imaging Mass Cytometry.
Based on protein expression profiles, we identified:
- 17 cancer cell populations,
- 20 tumour microenvironment (TME) cell populations.
We also mapped carboplatin in situ by detecting platinum.
Both epithelial and TME cell phenotypes differed between TNBC subtypes (Basal-like 1, BL1; Basal-like 2, BL2; Luminal androgen receptor, LAR; Mesenchymal, M; Mesenchymal stem-like), and PD-L1 positive and negative tumors (by IHC Ventana SP142). At baseline (pre-treatment), the presence of proliferating tumour cells expressing MHC-I and II and proliferating CD8 T cells expressing TCF1 were strongly predictive of pathological complete response (pCR) only in tumours receiving atezolizumab.
In addition, a high number of close spatial interactions (direct cell-to-cell contacts) between tumour cells and specific immune cells, such as B cells and CD8 granzyme B+ cytotoxic T cells, were also associated with a high likelihood of benefit from immunotherapy.
Studyng on-treatment samples revealed that sensitive tumours enriched in CD8 granzyme B+ T cells (stronger in atezo arm), whereas in resistant tumours the proportion of CD15+ tumour cells increased (only atezo arm), a potential new mechanism of adaptive immune resistance.
Investigating overall cellular dynamics, we found that immunotherapy distinctively remodels tumour structure Immune cells increased dramatically on-treatment (greatest with atezo) and decreased after treatment, accompanied by a lower in cancer cells and higher in stromal cells.
Multivariate modeling revealed that TME activation and tumor structure play pivotal roles in predicting treatment responses to immunotherapy Additionally, early on-treatment biopsies enhance predictive accuracy and could thus inform adaptive treatment strategies.
This would not have been possible without the collaboration between Fondazione Michelangelo and CRUK Cambridge Institute, the support by Ospedale San Raffaele and Fondazione Gianni Bonadonna, funders including Fondazione AIRC per la ricerca sul cancro, The Breast Cancer Research Foundation. Special thanks to the terrific work done by Xiao Qian Wang and all co-authors.
Very important: All imaging mass cytometry and clinical response data can be accessed via a Zenodo data repository for academic, non-commercial research! A terrific resource for the scientific community to build upon our findings.”
For the article click here.
Source: Giampaolo Bianchini/Twitter
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:17 27/11Vivek Subbiah: Treatment patterns and overall survival (OS) in patients with advanced NSCLC in three countries between 2011 and 2020
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows